UNSPSC 51294514: Seganserin

This classification denotes a serotonin antagonist with the molecular formula C29H27F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 197HL4EZCC, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-2-methyl-, dihydrochloride but generally known as seganserin, which bears US NIH Compound Identifier 71767. European Medicines Agency schedules Seganserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10472MIG.

UNSPSC 51294514 Seganserin is a Commodity code whose nominal scope does not align with state and local procurement activity currently posted under this classification. The recent opportunities tagged to this code involve procurement of naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are seganserin, a selective serotonin 5-HT1D receptor agonist. The mismatch suggests either miscoding in the state and local procurement systems or that this Commodity code is not actively solicited for its intended pharmaceutical target. State and local governments buying under pharmaceutical and OTC codes are primarily health departments, health and human services commissions, cooperative purchasing alliances, and county health systems procuring through formal competitive processes including RFPs, RFQs, and IFBs with multi-year terms and multiple-award structures.

Recent activity shows geographic spread across Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building. Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Minnesota's MMCAP, administered through the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across multiple state and local jurisdictions in Minnesota and Oregon, requiring vendor partnerships with three authorized wholesalers and compliance with cGMP and DSCSA. The code shows minimal relevant procurement activity under its stated pharmaceutical category, and prospecting under this code should focus on direct engagement with state health departments and cooperative purchasing alliances rather than on recent solicitation patterns.